CYP2D6 and epilepsy: The results show that there is no significant difference between the number of CYP2D6*10 genotypes not reaching the minimum effective concentration and the number of cases exceeding the minimum toxic concentration, indicating that the genetic polymorphism of CYP2D6*10 is not involved in the regulation of the plasma concentration of sodium valproate in patients with epilepsy.